Regulatory Post Marketing Surveillance Study on Nexavar®

• Status: Completed
• Trial end date: 2015-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This surveillance are to identify problems/questions regarding adverse events, factors that are considered to affect on safety and efficacy in the clinical practice of using Nexavar

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer
• Treatments: Sorafenib

Criteria

Inclusion Criteria:

• Patients with diagnosis of advanced RCC or HCC and decision taken by the physician to prescribe Nexavar.

Exclusion Criteria:

• Exclusion criteria must be read in conjunction with the local product information but patients who are participating in other interventional studies currently will be excluded.